NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AZEDRA (iobenguane I-131) is a radiopharmaceutical therapeutic that delivers iodine-131 via an iobenguane carrier molecule to target neuroendocrine tumors, particularly pheochromocytoma and paraganglioma. It works by concentrating radioactive iodine in tumor cells that express the norepinephrine transporter, delivering targeted radiation therapy.
Peak
Product is in peak commercial phase with moderate competitive pressure (30), suggesting stable team sizing and established market presence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AZEDRA roles are highly specialized, requiring expertise in rare oncology, radiopharmaceuticals, and niche market dynamics. Professionals on this product develop deep disease knowledge and work with small, focused teams in a stable peak-revenue environment.
Brand ManagerMedical Science Liaison
Worked on AZEDRA at Progenicyte Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.